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Abstract
Background:  The coexistence of endometrial and immune cells during decidualization is
preserved by the ability of endometrial cells to regulate the cytotoxic immune activity and their
capability to be resistant to immune-mediated apoptosis. These phenomena enable the survival of
endometrial ectopic cells. RCAS1 is responsible for regulation of cytotoxic activity. Metallothionein
expression seems to protect endometrial cells against apoptosis. The aim of the present study was
to evaluate RCAS1 and metallothionein expression in human ovarian and scar endometriomas in
relation to the presence of immune cells and their activity.
Methods: Metallothionein, RCAS1, CD25, CD69, CD56, CD16, CD68 antigen expression was
assessed by immunohistochemistry in ovarian and scar endometriomas tissue samples which were
obtained from 33 patients. The secretory endometrium was used as a control group (15 patients).
Results:  The lowest metallothionein expression was revealed in ovarian endometriomas in
comparison to scar endometriomas and to the control group. RCAS1 expression was at the highest
level in the secretory endometrium and it was at comparable levels in ovarian and scar
endometriomas. Similarly, the number of CD56-positive cells was lower in scar and ovarian
endometriomas than in the secretory endometrium. The highest number of macrophages was
found in ovarian endometriomas. RCAS1-positive macrophages were observed only in ovarian
endometriomas. CD25 and CD69 antigen expression was higher in scar and ovarian
endometriomas than in the control group.
Conclusion: The expression of RCAS1 and metallothionein by endometrial cells may favor the
persistence of these cells in ectopic localization both in scar following cesarean section and in
ovarian endometriosis.
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Background
The ovary is the most common location of the ectopic
endometrium occurrence in the pelvic genital organs.
Endometriosis is also found outside the genital tract. The
cesarean scar was the most common site of extragenital
endometriosis [1]. It was suggested in the 1950s that
endometrioma occurring in a cesarean scar might result
from specific endometrial changes depending on the preg-
nancy development [2]. Ovarian endometriosis, however,
was thought to be associated with retrograde menstrua-
tion [3]. The aforementioned two hypotheses in combina-
tion with the current opinion indicating that the
endometrial tissue acquires a secondary gestagen resist-
ance [4] indicates the natural ability of endometrial cells
to coexist with adjacent activated immune cytotoxic cells
within the decidua. This phenomenon is secondary to the
participation of endometrial cells in reproduction and
enables the creation of maternal immune tolerance
against fetal antigens.
The cells of the ectopic endometrium preserve an ability
of eutopic endometrial cells to regulate the cytotoxic
immune activity, for example, by the expression of many
immunomodulating factors (IL-1, IL-6, IL-8 and others)
[5] and by their resistance to immune-mediated apopto-
sis. A lower sensitivity to immune-induced apoptosis was
noticed in endometrial cells in ovarian cysts [6]. Both fea-
tures seem to be crucial for endometrial cell survival in
ectopic localization.
RCAS1, which until now has been thought to be responsi-
ble for tumor escape from immune surveillance in various
human cancer cells [7-9] seems to be an important factor
for cytotoxic activity regulation in the endometrium [10].
The expression of RCAS1 has been detected in the bone
marrow, the Waldeyer's ring, the placenta, the
endometrium, and the tubal mucosa thus indicating its
role in immune cells regulation [11-13].
Metallothionein (MT) is a cysteine-rich, low molecular
weight cytoplasmic protein. Its expression is related with
both processes concerning cell proliferation and cell death
[14]. MT expression correlated in cancer tissue with
reduced apoptosis in carcinoma cells [15]. Its expression
was observed in the endometrium and it was significantly
higher in the secretory than in the proliferative phase with
a peak during the implantation window [10,16,17]. MT
expression was also demonstrated in endometrial cancer
and ovarian endometriosis [16]. MT expression seems to
protect endometrial cells against apoptosis enabling them
to acquire resistance to immune-mediated apoptosis [10].
The absence of pelvic endometriosis is typical in patients
with abdominal wall endometrioma [18]. The reported
incidence of cesarean scar endometriosis ranges between
0.03 and 0.047 per cent and is reported until 2 years after
the surgical procedure [19]. The pelvic ectopic
endometrium might undergo decidualization during
pregnancy even in ovarian endometriosis, where the initi-
ation of implantation starts in the early proliferative
phase. On the contrary, scar endometriosis may form
chocolate cysts although it starts from the implantation of
a decidual cell. The formation of the ectopic decidua in
ovarian endometrioma is a well documented phenome-
non. Deciduosis is usually an asymptomatic phenome-
non and continues undetected throughout pregnancy
[20]. The ectopic endometrium preserves the ability to
undergo reversible decidualization, which is a phenome-
non typifying normal eutopic endometrium.
The aim of the present study was to evaluate RCAS1 and
metallothionein expression in ovarian and scar endome-
triomas in relation to immune cell presence and their
activity.
Materials and methods
Subjects
Forty-eight patients were included in our study. The mate-
rial was collected during routine surgical procedure in the
Department of Gynecology and Infertility of the Jagiello-
nian University in Krakow, Poland between January and
November 2005. No patient included in our study
received any hormonal treatment. Patients' consent was
obtained in all cases. The approval of the research pro-
gram by the Jagiellonian University Ethical Committee
was obtained prior to the study (KBET/89/B/2005). The
tissue samples were obtained during routine surgical pro-
cedures, were immediately fixed in 10% buffered formal-
dehyde solution and sent to the Pathomorphology
Department of the Jagiellonian University. Two experi-
enced pathomorphologists (K.G. and A.L) independently
evaluated the routinely stained (hematoxylin and eosin)
slides prepared from paraffin-embedded tissue material,
and selected the material adequate for further analysis.
Paraffin blocks were cut and used for immunohistochem-
istry.
Ovarian endometriomas
Ectopic human endometrium tissues were obtained from
19 non-menopausal infertile women, aged 25–37 years
from ovarian lesions during laparoscopic cyst enuclea-
tion. Before surgery the patients complained of dysmenor-
rhoea (12 cases), dyspareunia (14 cases) and chronic
pelvic pain (10 cases).
Abdominal wall endometriomas
Scar endometriomas were diagnosed in 15 patients aged
25–35 years in the incisional scar after cesarean elective
delivery with the presence of subcutaneous nodules infil-
trating the fascia (10 cases) and muscle (5 cases). The sur-Reproductive Biology and Endocrinology 2006, 4:41 http://www.rbej.com/content/4/1/41
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gical procedure was performed less than two years after
cesarean section. The patients complained of a cyclic local
pain and tenderness at the time of menstruation. Patients
after cesarean section with multiple pregnancies or exist-
ing pregnancy complications such as preterm deliveries,
hypertension, diabetes mellitus, and cases of fetal demise
were excluded from this study.
Control group
Eutopic human endometrium tissues were obtained from
14 non-menopausal fertile women, aged 29–41 years.
These patients underwent hysterectomy because of a
benign gynecological indication (leiomyomas). Tissue
samples were classified according to the menstrual cycle
phases. We included into the study only the tissue sam-
ples from the mid secretory cycle phase. The control sam-
ples from uterine corpus included the entire thickness of
the endometrium (basal and superficial part, composed
of stromal cells and glandular epithelial cells).
Immunohistochemistry
Immunohistochemical analysis was performed in the
Pathology Department of the Jagiellonian University.
Five-micrometer sections from each case were stained to
visualize expression of RCAS1, MT and CD16-, CD25-,
CD69-, CD56-positive cells (mainly lymphocytes) as well
as CD68+ cells, or macrophages. In all cases immunohis-
tochemistry was performed applying Envision method
using Dako Autostainer. The following antibodies were
applied: mouse monoclonal antibody Anti-RCAS1 (Med-
ical and Biological Laboratories, Naka-ku Nagoya, Japan
in DAKO Antibody Diluent with Background Reducing
Components-DAKO, Denmark, dilution 1:1000), mono-
clonal mouse antibody ImmunOTM (MP Biomedicals,
Inc., clone 1A12 in dilution 1:1000), CD56 (NCAM; NCL-
CD56-504, Novocastra) in dilution 1:100, CD69 (NCL-
CD69, Novocastra) in dilution 1:25, CD25 (Interleukin-2
Receptor, NCL-CD25-305, Novocastra) in dilution 1:25,
CD16 (NCL-CD16, Novocastra) in dilution 1:40, CD68
(Klone PG-M, Dako) in dilution 1:50, according the man-
ufacturer's instructions. Visualization of reaction products
was performed using AEC (3-amino-9-ethyl-carbazole) as
a chromogen (AEC Substrate Chromogen ready-to-use,
DAKO, Denmark) for 10 minutes at room temperature.
Sections were counterstained with hematoxylin and
mounted in glycergel. As a positive control a tonsil speci-
men was taken for RCAS1 and a breast cancer specimen
for metallothionein. All stainings were performed with
the same procedure but with the omission of the primary
antibody as a negative control. RCAS1 expression was
evaluated in entire slides in endometriosis area, in glan-
dular epithelium (superficial and of the glands) and the
stromal cells (fibroblasts), considering the per cent of pos-
itive cells and the intensity of the colour reaction. The
degree of metallothionein positivity was quantified as the
percentage of MT-positive cells in the endometriosis
lesion. The staining in epithelial and stromal cells of
endometriosis was evaluated. The scales used for estima-
tion of both marker staining are shown in Table 1.
The immune cells were calculated in an entire specimen,
in the region of endometriosis and an average cell number
per 1 hpf (high power field, objective magnification ×40)
was calculated. Variable scales were used to evaluate sem-
iquantitatively an amount of the cells, depending on their
general number in the specimen, summarized in Table 2.
The evaluation of immunohistochemical reactions was
performed independently by two histopathologists (K.G.
and A.L.).
Statistical analysis
The distribution of variables in the study groups of
women checked with the use of the Shapiro-Wilk test
showed that all of them were different from normal.
Therefore, nonparametric testing was employed. Statisti-
cal significance between the groups was determined by
the Kruskal-Wallis analysis of variance (ANOVA) test. The
Mann-Whitney U test was then used as applicable. The
Spearman rank test was used to evaluate interclass corre-
lation coefficients. All calculations were carried out with
the use of STATISTICA software v. 6 (StatSoft, USA, 2001).
Table 1: The scale used for evaluation of metallothionein and RCAS1 expression.
Antigen Immunoreactivity
0+ 1 + 2 + 3
RCAS1 No reactivity Weak (when observed any, also 
granular in paranuclear region) 
cytoplasmic staining pattern in up 
to 10% of positive cells
Marked cytoplasmic (sometimes 
together with membranous) 
staining in 11–30% of the cells
High expression – more than 
30% of positive cells
Metallothionein Lack of any positivity Weak staining in less than 5% of 
the cells
Moderate – various staining 
intensity but in <50% of the cells,
Strong – staining of more than 
50% of the cells.Reproductive Biology and Endocrinology 2006, 4:41 http://www.rbej.com/content/4/1/41
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Results
RCAS1 immunoreactivity was visible in the endometrial
epithelium without positive reaction in the proper stro-
mal cells.
RCAS1 immunopositivity was revealed in 57% of ovarian
endometriosis tissue samples, in 60% of scar endometri-
oma tissue samples and in all examined secretory
endometrial tissue samples (Figure 1.) The differences in
the distribution of MT immunoreactivity were found
between stromal cells and glandular cells in the tissue
samples derived from the scar and ovarian endometriosis.
No such alterations in MT distribution were observed
between samples in the control group (Figure 2.) Metal-
lothionein immunoreactivity was observed in glandular
epithelium of 21% ovarian endometriosis tissue samples,
94% scar endometriomas and in all secretory
endometrium tissue samples. Metallothionein immunop-
ositivity was shown in stromal cells of 69% ovarian
endometriosis tissue samples and in all stromal cells of
scar endometriomas. No MT immunoreactivity was
observed in stroma of secretory endometrium. Immune
cell presence (CD68, CD56 and CD16) and activity
(CD69, CD25) were assessed within stroma.
The statistical analysis of examined factors in ovarian
endometriosis, scar endometriomas and secretory
endometrium was performed by the Kruskal-Wallis anal-
ysis of variance (ANOVA) test and the results are pre-
sented in Table 3.
Analysis of RCAS1 immunoreactivity
Statistically significant lower RCAS1 expression was
observed in ovarian endometriosis than in the control
group (p = 0.002). Similarly, statistically significant lower
RCAS1 expression was identified in scar endometriosis in
comparison to the control group (p = 0.002). RCAS1
expression was on comparable levels in scar and ovarian
endometriosis (Table 4.) The RCAS1 positive macro-
phages were found in ovarian endometriomas, but they
were not detected either in the eutopic endometrium or in
scar endometriomas (Figure 3.)
RCAS1 expression in: scar endometriomas (A,B), ovarian  endometriomas (C,D) and secretory endometrium (E,F) Figure 1
RCAS1 expression in: scar endometriomas (A,B), ovarian 
endometriomas (C,D) and secretory endometrium (E,F). A – 
Weak positive glandular reaction in scar endometrioma (hor-
izontal arrows). Obj. magn. ×40; B-Very weak immunoreac-
tivity in glandular epithelium in scar endometrioma 
(horizontal arrow). Obj. magn. ×40; C – Weak immunoreac-
tivity in glandular epithelium of ovarian endometrioma (hori-
zontal arrow). Obj. magn. ×60; D – Strong immunoreactivity 
in glandular epithelium of ovarian endometrioma (horizontal 
arrows). Obj. magn. ×60; E – Strong immunoreactivity in 
glandular epithelium of the secretory endometrium, also of 
its basal part (horizontal arrows). Obj. magn. ×10; F – Strong 
immunoreactivity in glandular epithelium of secretory 
endometrium (horizontal arrow). Obj. magn. ×40.
Table 2: The scale used for evaluation of CD25, CD56, CD68, CD69, and CD16 antigens expression.
Antigen Immunoreactivity
0 1 +2 +3 +4 +
CD25 Lack of positive cells Single positive cells 1–5 positive cells/1 hpf More than 5 positive cells/
1 hpf
-
CD56 Lack of positive cells Single positive cells 1–5 positive cells/1 hpf More than 5 positive cells/
1 hpf
-
CD69 Lack of positive cells Single positive cells 1–5 positive cells/1 hpf More than 5 positive cells/
1 hpf
-
CD68 Lack of positive cells 1–5 positive cells/1 hpf 6–10 cells/1 hpf 11–20 positive cells/1 hpf More than 20 positive 
cells/1 hpf
CD16 Lack of positive cells 1–5 positive cells per 1 hpf 6–10 cells/1 hpf 11–20 positive cells/1 hpf More than 20 positive 
cells/1 hpfReproductive Biology and Endocrinology 2006, 4:41 http://www.rbej.com/content/4/1/41
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Analysis of MT immunoreactivity
A statistically significant lower MT immunoreactivity in
the glandular epithelium was identified in the ovarian
endometriosis in comparison to the scar endometriosis (p
< 0.001) and was also statistically significantly lower than
in the control group (p < 0.001). No differences in MT
expression in the glandular epithelium were observed
between scar endometriosis and the control group (Table
5.) MT immunoreactivity was statistically significantly
higher in the stroma of scar endometriosis when com-
pared to ovarian endometriosis (p < 0.001).
The difference in MT expression between the ovarian glan-
dular epithelium and ovarian stroma was observed and
was statistically significant (p = 0.01). However, no differ-
ences of MT expression in scar endometriosis between the
glandular epithelium and the stroma were found.
Analysis of immune cells presence (Table 6)
The number of macrophages was significantly higher in
ovarian endometriosis in comparison to the control
group, similarly it was observed to be statistically signifi-
cantly higher in scar endometriosis than in the control
group (p = 0.03).
CD69 antigen expression was on comparable levels in
ovarian and scar endometriosis, while in ovarian endome-
triosis it was significantly higher than in the control
group. Similarly, CD69 antigen expression was signifi-
cantly higher in scar endometriosis than in the control
group. CD25 antigen expression was statistically signifi-
cantly higher in scar endometriosis than in the control
group (p = 0.02). No differences in CD25 expression were
identified between ovarian endometriosis and the control
group. Statistically significantly lower CD25 expression
was detected in ovarian than in scar endometriosis (p =
0.005). The number of CD56-positive cells was identified
in ovarian and scar endometriosis on comparable levels,
but it was in both cases statistically significantly lower
than in the control group (p < 0.001). No differences in
CD16 antigen expression were observed between the
studied tissue samples and the control group.
Discussion
RCAS1 immunoreactivity was more prominent in the
secretory endometrium than in scar and ovarian endome-
triomas. Stronger Metallothionein expression was deter-
mined in scar endometriomas and in secretory
endometrium than in ovarian endometriosis. The altera-
tions in RCAS1 and Metallothionein expression are
accompanied by changes in CD25, CD56 and CD69 anti-
gens expression on immune cells.
A decrease of CD25 antigen expression with a concomi-
tant increase of CD69 expression has been observed in the
endometrium according to the menstrual cycle changes
[21]. Chao et al. concluded that there might exist a factor
or factors capable of selective suppression of activated
cytotoxic cells. RCAS1 could be considered as a factor to
play that role. Its expression increases significantly during
the secretory cycle phase. In our previous report a signifi-
cantly lower RCAS1 expression was noticed in ovarian
endometriosis in comparison to endometrial carcinoma
[10]. RCAS1 expression was growing in the eutopic
endometrium simultaneously with the growth of the
number of CD56-positive cells and CD69 antigen expres-
sion. In the present study a correlation between CD56 and
CD69 expression was observed in ovarian endometrio-
mas (R = 0.53, p = 0.018) as well as in scar endometrio-
mas (R = 0.52, p = 0.04). A decrease of the number of
MT expression in: scar endometriomas (A,B), ovarian  endometriomas (C,D) and secretory endmetrium (E,F) Figure 2
MT expression in: scar endometriomas (A,B), ovarian 
endometriomas (C,D) and secretory endmetrium (E,F). A – 
Moderate positive stromal reaction in scar endometrioma 
tissue (vertical arrows). Obj. magn. ×40; B-Strong immunore-
activity in glandular epithelium of scar endometrioma (hori-
zontal arrow) Obj. magn. ×10; C – Moderate 
immunoreacitvity in stromal cells of ovarian endometrioma 
(vertical arrows). Obj. magn. ×40; D – Very weak immunore-
activity in glandular epithelium of ovarian endometrioma 
(vertical arrows). Obj. magn. ×40; E – Strong immunoreactiv-
ity in glandular epithelium of secretory endometrium (hori-
zontal arrows) and negative stromal cells (x). Obj. magn. ×40. 
F – Strong MT immunoreactivity in glandular epithelium of 
the secretory endometrium (horizontal arrow). Obj. magn. 
×60.Reproductive Biology and Endocrinology 2006, 4:41 http://www.rbej.com/content/4/1/41
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CD56-positive cells in scar and ovarian endometrioses
seems to remain in agreement with described NK cell dys-
function, which is considered to contribute to the patho-
genesis of endometriosis [22]. Diminished NK cell activity
has been observed in the peritoneal fluid of women with
endometriosis [23]. The main task of scientists is focused
on the question whether this dysfunction is primary or
secondary to the development of ovarian endometriosis.
The expression of the killer inhibitory receptors (KIRs; for
example CD158a) on NK cells associated with the
decrease of the NK cell activity might indicate that the NK
cell changes are the primary event [22]. On the contrary, a
higher expression of class I human lymphocyte antigens
on endometrial cells surviving in ectopic localization [24]
suggests the secondary resistance to natural killer-medi-
ated cytolysis [25]. The RCAS1 expression observed in this
study in both scar and ovarian endometriomas points to
the possibility of inhibition of cytotoxic immune
response, which might be secondary to the physiological
ability of endometrial cells to regulate immune cell activ-
ity. The decreased RCAS1 expression in scar and ovarian
endometriomas in comparison to the eutopic secretory
endometrium might result from the lower number of NK
cells. NK dysfunction in endometriosis was found to be
related to the diminished macrophages ability to present
antigens [26].
Macrophages seem to play a central role in the immunob-
iology of endometriosis [27]. The recent evidence suggests
that ovarian macrophages migration is a result of RANTES
secretion into the environment of endometriomas [28],
and their numerous products (IL-1beta, TNF-alfa, Il-6, Il-
Destroyed epithelial layer of an endometrial ovarian cyst Figure 3
Destroyed epithelial layer of an endometrial ovarian cyst. 
The covering of it composed mainly of macrophages, with 
strong RCAS1 expression (B, C, D). RCAS1-positive macro-
phages present also loosely in the cyst fluid (A). Obj magn.: 
A, C, D ×40; B ×20.
Table 3: The results of statistical analysis of metallothionein (MT), RCAS1, CD68, CD56, CD16, CD25 and CD69 expression in ovarian 
endometriosis, scar endometriomas and secretory endometrium performed by Kruskal-Wallis analysis of variance (ANOVA) test. (± 
SE – standard error).
Antigens Ovarian endometriosis Scar endometriosis Control group p
RCAS1 0.684 (± 0.149) 0.666 (± 0.168) 1.583 (± 0.173) 0.0026
MT – glandular epithelium 0.211 (± 0.159) 1.800 (± 0.179) 2.167 (± 0.185) <0.001
MT – stroma 1.000 (± 0.162) 2.200 (± 0.182) 0.000 (± 0.189) <0.001
CD56 0.579 (± 0.135) 0.400 (± 0.152) 2.000 (± 0.186) <0.001
CD16 1.789 (± 0.240) 1.600 (± 0.270) 2.300 (± 0.331) 0.292
CD68 2.579 (± 0.227) 2.000 (± 0.256) 2.800 (± 0.313) 0.024
CD25 0.421 (± 0.239) 1.667 (± 0.268) 0.300 (± 0.329) 0.009
CD69 0.895 (± 0.259) 1.200 (± 0.292) 0.300 (± 0.357) 0.167
Table 4: The immunhistochemical analysis of RCAS1 expression in glandular epithelium
Groups Part of endometrium RCAS1 immunoreactivity*
0+ 1 + 2 + 3
Ovarian endometriosis (n = 19) Glandular epithelium 42 (8) 47 (9) 11 (2) -
Scar endometriosis (n = 15) Glandular epithelium 40 (6) 53 (8) 7 (1) -
Control group (n = 14) Glandular epithelium - 57 (8) 35 (5) 8 (1)
*percentage of cases; (n-total number of cases)Reproductive Biology and Endocrinology 2006, 4:41 http://www.rbej.com/content/4/1/41
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8, MMP-9, VEGF and others) may be involved in the onset
and development of endometriosis [27]. In our present
study the highest number of macrophages was identified
in ovarian endometriosis when compared to scar
endometriosis and to the control group. Interestingly,
only ovarian macrophages were RCAS1 positive (Fig. 3).
The presence of RCAS1-positive macrophages in ovarian
endometriosis was already reported in our previous pre-
liminary study [30]. Until now RCAS1-positive macro-
phages were observed in the bone marrow, peripheral
blood of patients with Hodgkin lymphoma, nasal polyps
and in immune mediated liver disease [11,31,32]. Per-
haps the alteration of macrophage-NK cells and macro-
phage-cytotoxic T lymphocyte interactions might help the
cells survive in ectopic localization. In scar endometrio-
mas no RCAS1-positive macrophages were observed, but
this is the situation when the primary lesion develops dur-
ing the immune tolerance against fetal antigens in preg-
nancy maintenance and this protection seems to facilitate
the development of the endometriomas foci. Our results
seem to confirm the clinical observations of scar endome-
triomas. Although the implantation of decidual cells
might be induced iatrogenically by mechanical transplan-
tation, endometriomas do not develop in all scars follow-
ing cesarean sections and occur more frequently following
elective cesarean sections performed during the mainte-
nance of immune tolerance during pregnancy [33-35].
Implanting endometrial cells within the cesarean scar pos-
sesses both the ability to regulate the activity of immune
response and a high resistance to immune mediated
apoptosis similar to eutopic endometrial cells during the
secretory cycle phase [6,29]. The recruitment of lym-
phocytes to decidua takes place during the whole course
of pregnancy [36], pregnancy termination is related with
the termination of their activity inhibition [37], decidual
cells are extremely exposed to immune mediated apopto-
sis. The resistance to immune mediated apoptosis of the
endometrial cells can be related to MT expression [38-41].
The increase of MT endometrial immunoreactivity during
the implantation window seems to be secondary to the
growing cytotoxic activity. A higher level of MT expression
has been demonstrated in the eutopic endometrium
simultaneously with the increasing number and activity of
cytotoxic cells [10]. Endometriosis cells are characterized
by the inability to transmit a "death" signal [42]. In the
present study MT expression in ovarian endometriosis was
at the lowest level when compared to the eutopic
endometrium and scar endometriosis. However, it was at
the comparable level in scar endometriosis and the con-
Table 6: Density of CD56+, CD16+, CD68+, CD25+ and CD69+ cells in the endometrial stroma.
Tissues samples CD – antigens The number of lymphocytes
0 + 1+ 2+ 3+ 4
Ovarian endometriosis (n = 19) CD56 47 (9) 47 (9) 6 (1) - -
CD16 6 (1) 41 (8) 26 (5) 21 (4) 6 (1)
CD68 - 22 (4) 26 (5) 26 (5) 26 (5)
CD25 78 (15) 22 (4) - - -
CD69 47 (9) 26 (5) 15 (3) 12 (2) -
Scar endometriosis (n = 15) CD56 66 (10) 27 (4) 7 (1) - -
CD16 19 (3) 27 (4) 27 (4) 27 (4) -
CD68 11 (2) 11 (2) 37 (5) 41 (6) -
CD25 41 (6) - 11 (2) 48 (7) -
CD69 48 (7) 19 (3) 7 (1) 19 (3) 7 (1)
Control group (n = 10) CD56 - 10 (1) 80 (8) 10 (1) -
CD16 - 20 (2) 40 (4) 30 (3) 10 (1)
CD68 - 20 (2) 80 (8) - -
CD25 70 (7) 30 (3) - - -
CD69 80 (8) 10 (1) 10 (1) - -
*percentage of cases; (n-total number of cases)
Table 5: The immunhistochemical analysis of metallothionein expression in the glandular epithelium and stroma.
Groups Part of endometrium Metallothionein immunoreactivity*
0+ 1 + 2 + 3
Ovarian endometriosis (n = 19) Glandular epithelium 78 (15) 22 (4) - -
Stroma 31 (6) 38 (7) 31 (6) -
Scar endometriosis (n = 15) Glandular epithelium 7 (1) 27 (4) 46 (7) 20 (3)
Stroma - 27 (4) 27 (4) 46 (7)
Control group (n = 14) Glandular epithelium - 28 (4) 44 (6) 28 (4)
Stroma 100(14) - - -
*percentage of cases; (n-total number of cases)Reproductive Biology and Endocrinology 2006, 4:41 http://www.rbej.com/content/4/1/41
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trol group. High MT expression in scar endometriomas
was accompanied by the growing number of CD25- and
CD69-positive immune cells, while low MT expression in
ovarian endometriomas accompanied by a lower number
of CD25- and CD69-positive immune cells coexisted with
the presence of RCAS1-positive macrophages. Thus, mac-
rophages probably play an additional role in the NK cells
activity restrictions. Moreover, differences in MT expres-
sion between epithelial cells and stroma were identified,
what seems to confirm the reports on differences between
apoptosis levels in the glandular epithelium and stroma
in ovarian endometrioid cyst [43,44].
The expression of RCAS1 and metallothionein by
endometrial cells is important for the coexistence of acti-
vated immune cells together with endometrial cells dur-
ing decidualization in secretory cycle phase. This
expression may favor the persistence of endometrial cells
in ectopic localization both in scar following cesarean sec-
tion and in ovarian endometriosis.
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